Abcam, ab239014, Anti-PHAPI2 / APRIL antibody [EPR14588] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PHAPI2 / APRIL antibody. Carrier free. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14588,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, Flow Cyt (Intra), WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab239014 is the carrier-free version of
ab200836
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PHAPI2 also known as APRIL is a protein with various roles in cellular mechanisms. The protein has a molecular mass of around 32 kDa and it is found in many tissues including the spleen liver and lymph nodes. PHAPI2 acts as part of the tumor necrosis factor ligand superfamily where it influences cell proliferation and survival. This protein interacts with receptors such as BCMA and TACI impacting immune system functions.
Biological function summary
PHAPI2 regulates immune system processes by playing a role in B cell development and activity. It functions as part of larger protein complexes binding with proteins such as BCMA to influence signaling pathways. The interactions within these complexes help modulate processes critical for proper immune response and maintenance of immune system homeostasis.
Pathways
PHAPI2 is deeply involved in both the NF-kB signaling pathway and the PI3K/AKT pathway. These pathways are essential for cellular growth survival and proliferation. Through its involvement PHAPI2 also connects with proteins like NF-kB and AKT1 which are key regulatory proteins within these pathways. This connection enables PHAPI2 to act as a node integrating signals for various cellular responses.
PHAPI2 associations include autoimmune diseases and cancer. Aberrant expression or mutations in PHAPI2 are linked to conditions like systemic lupus erythematosus and certain B cell malignancies. Through these disorders PHAPI2 interacts with proteins such as BAFF and CD40 which are important for disease progression and immune dysregulation. This makes PHAPI2 a potential therapeutic target for intervention in these conditions.